Flputnam Investment Management Co. Purchases 27,425 Shares of Johnson & Johnson $JNJ

Key Points

• Flputnam Investment Management increased its Johnson & Johnson stake by 40.4% in the second quarter, purchasing 27,425 shares and bringing its holdings to 95,241 shares valued at approximately $24.2 million. Institutional investors collectively own 69.55% of J&J.
• Johnson & Johnson reported quarterly EPS of $2.90, exceeding estimates by $0.06, while revenue rose 6.6% year over year to $25.31 billion. The company maintained 2026 EPS guidance of $11.60–$11.75 and declared a $1.34 quarterly dividend, representing a 2.0% yield.
• Analyst sentiment remains favorable, with a consensus rating of “Moderate Buy” and an average price target of $272.83. However, shares trade near their 52-week high at roughly 31 times earnings, while company insiders sold $23.1 million of stock over the past three months.

Flputnam Investment Management Co. lifted its holdings in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 40.4% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 95,241 shares of the company's stock after buying an additional 27,425 shares during the quarter. Flputnam Investment Management Co.'s holdings in Johnson & Johnson were worth $24,188,000 at the end of the most recent quarter.

Several other institutional investors have also recently made changes to their positions in the stock. Davidson Investment Advisors increased its position in shares of Johnson & Johnson by 2.1% during the second quarter. Davidson Investment Advisors now owns 6,977 shares of the company's stock valued at $1,772,000 after buying an additional 146 shares during the period. Sheets Smith Wealth Management boosted its position in shares of Johnson & Johnson by 3.9% in the second quarter. Sheets Smith Wealth Management now owns 11,131 shares of the company's stock valued at $2,827,000 after acquiring an additional 422 shares during the period. Greenleaf Trust grew its stake in Johnson & Johnson by 1.2% during the second quarter. Greenleaf Trust now owns 86,071 shares of the company's stock valued at $21,859,000 after acquiring an additional 985 shares in the last quarter. Capital Advisors Inc. OK increased its holdings in Johnson & Johnson by 0.6% during the 2nd quarter. Capital Advisors Inc. OK now owns 22,507 shares of the company's stock worth $5,716,000 after acquiring an additional 141 shares during the period. Finally, Trustmark Bank Trust Department raised its position in shares of Johnson & Johnson by 6.4% in the second quarter. Trustmark Bank Trust Department now owns 14,007 shares of the company's stock worth $3,557,000 after buying an additional 839 shares in the last quarter. Hedge funds and other institutional investors own 69.55% of the company's stock.

Johnson & Johnson Trading Down 0.7%

Shares of JNJ opened at $267.20 on Thursday. Johnson & Johnson has a fifty-two week low of $173.33 and a fifty-two week high of $281.07. The firm has a market cap of $643.93 billion, a price-to-earnings ratio of 30.96, a PEG ratio of 2.57 and a beta of 0.24. The firm has a 50 day moving average price of $262.88 and a 200-day moving average price of $245.62. The company has a debt-to-equity ratio of 0.44, a quick ratio of 0.81 and a current ratio of 1.09.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last released its earnings results on Wednesday, July 15th. The company reported $2.90 EPS for the quarter, beating the consensus estimate of $2.84 by $0.06. The company had revenue of $25.31 billion for the quarter, compared to analyst estimates of $25.06 billion. Johnson & Johnson had a net margin of 21.48% and a return on equity of 32.42%. The firm's quarterly revenue was up 6.6% compared to the same quarter last year. During the same quarter last year, the firm earned $2.77 EPS. Johnson & Johnson has set its FY 2026 guidance at 11.600-11.750 EPS. As a group, equities research analysts forecast that Johnson & Johnson will post 11.61 earnings per share for the current year.

Johnson & Johnson Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Tuesday, September 8th. Stockholders of record on Tuesday, August 25th were issued a $1.34 dividend. The ex-dividend date was Tuesday, August 25th. This represents a $5.36 annualized dividend and a dividend yield of 2.0%. Johnson & Johnson's dividend payout ratio (DPR) is currently 62.11%.

Insider Activity

In related news, EVP Vanessa Broadhurst sold 23,054 shares of the company's stock in a transaction on Monday, July 20th. The shares were sold at an average price of $251.27, for a total transaction of $5,792,778.58. Following the completion of the sale, the executive vice president directly owned 23,003 shares in the company, valued at $5,779,963.81. This represents a 50.06% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, EVP Jennifer Taubert sold 15,000 shares of the stock in a transaction on Monday, August 17th. The shares were sold at an average price of $263.36, for a total transaction of $3,950,400.00. Following the sale, the executive vice president directly owned 194,451 shares of the company's stock, valued at $51,210,615.36. The trade was a 7.16% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 87,569 shares of company stock valued at $23,064,544 in the last three months. Corporate insiders own 0.16% of the company's stock.

Wall Street Analysts Forecast Growth

A number of brokerages have weighed in on JNJ. Weiss Ratings upgraded Johnson & Johnson from a "buy (b-)" rating to a "buy (b)" rating in a research note on Friday, July 24th. Johnson Rice restated a "buy" rating on shares of Johnson & Johnson in a research report on Monday, August 3rd. Citigroup lifted their target price on shares of Johnson & Johnson from $285.00 to $298.00 and gave the company a "buy" rating in a research report on Wednesday, July 8th. Morgan Stanley raised their price objective on shares of Johnson & Johnson from $284.00 to $294.00 and gave the company an "overweight" rating in a research report on Thursday, July 16th. Finally, Guggenheim lifted their price objective on shares of Johnson & Johnson from $270.00 to $287.00 and gave the stock a "buy" rating in a report on Thursday, August 6th. One research analyst has rated the stock with a Strong Buy rating, eighteen have issued a Buy rating and six have issued a Hold rating to the company. Based on data from MarketBeat.com, Johnson & Johnson has an average rating of "Moderate Buy" and a consensus target price of $272.83.

Key Stories Impacting Johnson & Johnson

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: At the Wells Fargo Healthcare Conference, Johnson & Johnson highlighted growth opportunities in MedTech, with cardiovascular products taking center stage. Management’s focus on high-end, innovative devices supports the company’s longer-term growth outlook. Johnson & Johnson Eyes High-End MedTech Growth as Cardiovascular Takes Center Stage
• Positive Sentiment: JNJ is preparing to present 24 abstracts at Psych Congress 2026, including pivotal Phase 3 CAPLYTA data in bipolar mania and new SPRAVATO analyses. The data could strengthen confidence in the company’s neuropsychiatry pipeline and future pharmaceutical growth. Johnson & Johnson Neuropsychiatry Data
• Positive Sentiment: Jim Cramer characterized the recent weakness as a buying opportunity, reinforcing the view that JNJ’s defensive profile, diversified healthcare operations, and dividend appeal may attract investors during market uncertainty. Cramer Says It’s Time to Buy the Dip on JNJ
• Neutral Sentiment: Analysts and market commentary continue to view JNJ as a defensive stock ahead of inflation data and the Federal Reserve’s next rate decision. That positioning may support demand, but macroeconomic uncertainty is also increasing day-to-day volatility. Defensive Stocks Ahead of CPI and the Fed
• Negative Sentiment: JNJ recently declined more than the broader market, suggesting profit-taking or increased sensitivity to market-wide selling. With shares near their 52-week high and trading at roughly 31 times earnings, valuation may be limiting near-term upside despite solid earnings and full-year EPS guidance. Johnson & Johnson Sees a More Significant Dip Than the Broader Market

About Johnson & Johnson

Johnson & Johnson NYSE: JNJ is a global healthcare company that develops, manufactures and markets pharmaceutical and medical device products. Founded in 1886 and headquartered in New Brunswick, New Jersey, the company serves patients, healthcare professionals and institutions in markets around the world.

Johnson & Johnson operates through two primary business segments: Innovative Medicine and MedTech. Innovative Medicine focuses on prescription treatments in areas including immunology, oncology, neuroscience, cardiovascular and metabolic disease, infectious diseases, and pulmonary hypertension.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.